Therapeutic effects and mechanism of human amnion-derived mesenchymal stem cells on hypercoagulability in a uremic calciphylaxis patient

References

• Garcia-Lozano JA, Ocampo-Candiani J, Martinez-Cabriales SA, et al. An update on calciphylaxis. Am J Clin Dermatol. 2018;19(4):1–8.
   PubMed Web of Science ®Google Scholar
• Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018;378(18):1704–1714.
   PubMed Web of Science ®Google Scholar
• Kodumudi V, Jeha GM, Mydlo N, et al. Management of cutaneous calciphylaxis. Adv Ther. 2020;37(12):4797–4807.
   PubMed Web of Science ®Google Scholar
• Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61(6):2210–2217.
   PubMed Web of Science ®Google Scholar
• Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol. 2016;27(11):3421–3429.
   PubMed Web of Science ®Google Scholar
• Marin BG, Aghagoli G, Hu SL, et al. Calciphylaxis and kidney disease: a review. Am J Kidney Dis. 2022;81(2):232–239.
   PubMed Web of Science ®Google Scholar
• Jo H, Brito S, Kwak BM, et al. Applications of mesenchymal stem cells in skin regeneration and rejuvenation. Int J Mol Sci. 2021;22:2410.
   PubMed Web of Science ®Google Scholar
• Aghajani Nargesi A, Lerman LO, Eirin A. Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges. Stem Cell Res Ther. 2017;8(1):273.
   PubMed Web of Science ®Google Scholar
• Liu Y, Guo Y, Bao S, et al. Bone marrow mesenchymal stem cell-derived exosomal microRNA-381-3p alleviates vascular calcification in chronic kidney disease by targeting NFAT5. Cell Death Dis. 2022;13(3):278.
   PubMed Web of Science ®Google Scholar
• Liu QW, Huang QM, Wu HY, et al. Characteristics and therapeutic potential of human Amnion-Derived stem cells. Int J Mol Sci. 2021;22:970.
   PubMedGoogle Scholar
• Qin L, Zhang J, Xiao Y, et al. A novel long-term intravenous combined with local treatment with human amnion-derived mesenchymal stem cells for a multidisciplinary rescued uremic calciphylaxis patient and the underlying mechanism. J Mol Cell Biol. 2022;14:mjac010.
   PubMed Web of Science ®Google Scholar
• Dobry AS, Ko LN, St John J, et al. Association between hypercoagulable conditions and calciphylaxis in patients with renal disease: a Case-Control study. JAMA Dermatol. 2018;154(2):182–187.
   PubMed Web of Science ®Google Scholar
• el-Azhary RA, Arthur AK, Davis MDP, et al. Retrospective analysis of tissue plasminogen activator as an adjuvant treatment for calciphylaxis. JAMA Dermatol. 2013;149(1):63–67.
   PubMed Web of Science ®Google Scholar
• Carter A, Ortega-Loayza AG, Barrett J, et al. Calciphylaxis with evidence of hypercoagulability successfully treated with unfractionated heparin: a multidisciplinary approach. Clin Exp Dermatol. 2016;41(3):275–278.
   PubMed Web of Science ®Google Scholar
• Liu H, Jiang C, La B, et al. Human amnion-derived mesenchymal stem cells improved the reproductive function of age-related diminished ovarian reserve in mice through ampk/FoxO3a signaling pathway. Stem Cell Res Ther. 2021;12(1):317.
   PubMed Web of Science ®Google Scholar
• Reed MD, Van Nostran W. Assessing pain intensity with the visual analog scale: a plea for uniformity. J Clin Pharmacol. 2014;54(3):241–244.
   PubMed Web of Science ®Google Scholar
• Harris C, Bates-Jensen B, Parslow N, et al. Bates-Jensen wound assessment tool: pictorial guide validation project. J Wound Ostomy Continence Nurs. 2010;37(3):253–259.
   PubMed Web of Science ®Google Scholar
• Blome C, Baade K, Debus ES, et al. The "Wound-QoL": a short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair Regen. 2014;22(4):504–514.
   PubMed Web of Science ®Google Scholar
• Neitzel CD. Biopsy techniques for skin disease and skin cancer. Oral Maxillofac Surg Clin North Am. 2005;17(2):143–146.
   PubMedGoogle Scholar
• Wang NN, Qin LJ, Liu K, et al. Multidisciplinary regenerative treatment and mechanisms for rescuing a severe calciphylaxis patient with human amnion-derived mesenchymal stem cells. Natl Med J China. 2022;102:2217–2221.
   Google Scholar
• Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133–146.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Cropley TG. Possible role of hypercoagulability in calciphylaxis: review of the literature. J Am Acad Dermatol. 2011;64(2):405–412.
   PubMed Web of Science ®Google Scholar
• El-Azhary RA, Patzelt MT, McBane RD, et al. Calciphylaxis: a disease of pannicular thrombosis. Mayo Clin Proc. 2016;91(10):1395–1402.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: d -Dimer. J Am Coll Cardiol. 2017;70(19):2411–2420.
   PubMed Web of Science ®Google Scholar
• de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010;36(1):7–17.
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26–S34.
   PubMed Web of Science ®Google Scholar
• Paar M, Rossmann C, Nusshold C, et al. Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS One. 2017;12(8):e0182997.
   PubMed Web of Science ®Google Scholar
• Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906–918.
   PubMed Web of Science ®Google Scholar
• Netsch P, Elvers-Hornung S, Uhlig S, et al. Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine. Stem Cell Res Ther. 2018;9(1):184.
   PubMedGoogle Scholar
• Al Subayyil A, Basmaeil YS, Alenzi R, et al. Human placental mesenchymal stem/stromal cells (pMSCs) inhibit agonist-induced platelet functions reducing atherosclerosis and thrombosis phenotypes. J Cell Mol Med. 2021;25(19):9268–9280.
   PubMed Web of Science ®Google Scholar
• Coppin L, Sokal E, Stephenne X. Thrombogenic risk induced by intravascular mesenchymal stem cell therapy: current status and future perspectives. Cells. 2019;8(10):1160.
   PubMed Web of Science ®Google Scholar
• Liao L, Shi B, Chang H, et al. Heparin improves BMSC cell therapy: anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy. Theranostics. 2017;7(1):106–116.
   PubMed Web of Science ®Google Scholar
• Coppin L, Najimi M, Bodart J, et al. Clinical protocol to prevent thrombogenic effect of Liver-Derived mesenchymal cells for Cell-Based therapies. Cells. 2019;8(8):846.
   PubMed Web of Science ®Google Scholar
• Abbasi-Kangevari M, Ghamari SH, Safaeinejad F, et al. Potential therapeutic features of human amniotic mesenchymal stem cells in multiple sclerosis: immunomodulation, inflammation suppression, angiogenesis promotion, oxidative stress inhibition, neurogenesis induction, MMPs regulation, and remyelination stimulation. Front Immunol. 2019;10:238.
   PubMed Web of Science ®Google Scholar
• Phermthai T, Thongbopit S, Pokathikorn P, et al. Carcinogenicity, efficiency and biosafety analysis in xeno-free human amniotic stem cells for regenerative medical therapies. Cytotherapy. 2017;19(8):990–1001.
   PubMed Web of Science ®Google Scholar
• Shi R, Lian W, Jin Y, et al. Role and effect of vein-transplanted human umbilical cord mesenchymal stem cells in the repair of diabetic foot ulcers in rats. Acta Biochim Biophys Sin (Shanghai). 2020;52(6):620–630.
   PubMed Web of Science ®Google Scholar